Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIVEC HEAT for BCG-unresponsive non-muscle-invasive bladder cancer
ISRCTN49174478Phase 3Recruiting
- Sponsor
- University of Leicester
- Start
- Apr 2025
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of mitomycin c in non-muscle-invasive bladder cancer (NMIBC), transitional cell carcinoma of the bladder (TCC) and Bladder cancer in situ (CIS), sponsored by University of Leicester. Primary endpoints: Complete response at 3 months and Median duration of high-grade recurrence-free survival. Started Apr 2025; status: recruiting.
02
Drugs
mitomycin c
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma of the bladder (TCC)Bladder cancer in situ (CIS)
Beyond the preview
Go deeper on ISRCTN49174478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN49174478.